Health News Releases

  • Today May 22
February 26, 2015 13:45
Gore Global Registry for Endovascular Aortic Treatment Reaches 2,500 Enrolled Patients
W. L. Gore & Associates, Inc. (Gore, www.goremedical.com) reports that more than 2,500 patients have been enrolled in the Gore Global Registry for Endovascular Aortic Treatment (GREAT). The registry i
February 25, 2015 14:40
Management Buy out of Synexus Backed by LDC; the Deal Will Enable It to Further Expand Its Global Network
Today (Monday 23rd February 2015) Synexus, the world’s largest multi-national company dedicated to the recruitment and running of clinical trials at its own research centres across the globe, complete
February 25, 2015 13:25
Quintiles Appoints Elgar Peerschke as President of Advisory Services
Quintiles today announced the appointment of Elgar Peerschke to serve as president, Advisory Services. In this role, Peerschke is responsible for leading Quintiles’ Advisory Services organization and
February 24, 2015 14:00
Second Sight to Present at the 27th Annual ROTH Conference on March 9, 2015
Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide functional vision to blind pati
February 24, 2015 13:30
Ferring Pharmaceuticals Acquires Novel Drug Delivery Technology From CTCBIO Inc.
Ferring Pharmaceuticals announced today that it has signed an agreement with CTCBIO Inc. of Seoul, South Korea to acquire rights to a novel oral drug delivery technology. Ferring’s success in devel
February 24, 2015 11:55
FDA Grants Seven Years’ Market Exclusivity to Eagle Pharmaceuticals’ Ryanodex for the Treatment of Malignant Hyperthermia
Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) today confirmed that the U.S. Food and Drug Administration (FDA) has granted seven years of market exclusivity in the U.S. to Ryano
February 23, 2015 23:25
Quintiles Named to FORTUNE Magazine's 2015 List of “World’s Most Admired Companies”
Quintiles, the world’s largest biopharmaceutical services company, has been named to FORTUNE magazine’s “World’s Most Admired Companies” list for 2015. Quintiles is ranked third overall in FORTUNE’
February 23, 2015 11:55
REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Commission (EC) has approved REVLIMID® (lenalidomide) for the treatment o
February 23, 2015 11:05
Ferring Pharmaceuticals acquires two phase III ready orthobiologic product candidates from BioSET
Ferring Pharmaceuticals announced today that it has acquired the assets of BioSurface Engineering Technologies, Inc. (BioSET), including two phase III ready orthobiologic product candidates designed t
February 17, 2015 16:00
CellProthera, Pioneer in Cell Regenerative Therapy, Awarded the 2014 UBISTART Prize
CellProthera has been awarded the 2014 UBISTART prize, under the aegis of UBIFRANCE and the Galien Foundation based in New York. This initiative rewards innovative French start-ups for making major ad
February 17, 2015 14:00
Eppendorf Announces New CryoCube® Ultra-Low Temperature Freezers
The new CryoCube (www.nbsc.com/freezers) F570, F570h, FC660, and FC660h ultra-low temperature freezers combine maximum sample security with improved functionality. New advancements decrease power cons
February 13, 2015 13:10
Manufacturing Authorization of Gene Therapy Medicinal Products Granted to CELLforCURE, the LFB Group Subsidiary Specialized in Innovative Therapies
CELLforCURE, a pharmaceutical establishment since October 2013 for the manufacturing of cell therapy medicinal products, was granted a new manufacturing authorization on January 30th, 2015. Delivered
February 12, 2015 15:25
Addition of Stent Thrombectomy in Treatment of Acute Ischemic Stroke Patients Reduces Disability in Global Studies
Research presented today at the International Stroke Conference (ISC) in Nashville, Tenn. and published online in The New England Journal of Medicine (NEJM) found that the addition of the Solitaire™ D
February 10, 2015 16:00
Takeda Announces That the First Interim Analysis of the Phase 3 Study of Oral Ixazomib in Patients with Relapsed or Refractory Multiple Myeloma Met the Primary Endpoint of Improvement in Progression-Free Survival
Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the randomized, double-blind, placebo-controlled TOURMALINE-MM1 pivotal Phase 3 trial evaluating the safety and efficacy of ixazom
February 02, 2015 17:50
Ferring Pharmaceuticals Moves to Strengthen Growth with Appointment of Chief Medical and Chief Scientific Officers
Ferring Pharmaceuticals announced today the appointment of Pascal Danglas, MD as Executive Vice President and Chief Medical Officer and Per Falk, MD, PhD as Executive Vice President and Chief Scientif
January 30, 2015 17:30
Ortho Clinical Diagnostics and Quotient Announce Agreement to Commercialize Innovative Transfusion Diagnostic Platform, MosaiQ™
Ortho-Clinical Diagnostics, Inc. (“OCD”) announced it has entered into an exclusive agreement with commercial-stage diagnostics company Quotient Limited (“Quotient”) to distribute and sell Quotient’s
January 28, 2015 10:45
Celgene Receives Positive CHMP Opinion for ABRAXANE® for First-Line Treatment of Patients with Non-Small Cell Lung Cancer
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (
January 27, 2015 17:30
New large-scale study to investigate effect of tiotropium + olodaterol Respimat® on exacerbations in COPD
For media outside the US, the UK and Canada Boehringer Ingelheim today announced that the first patient has been enrolled into its large-scale DYNAGITO® study.[1] It will assess the potential benef
January 20, 2015 22:05
Eppendorf Announces New BioFlo® 320 Bench Scale Bioprocess Control Station
The BioFlo 320 is truly a step into the future for Eppendorf as a bioprocess equipment manufacturer. New features including autoclavable and single-use vessel flexibility, intelligent sensors, and IP
January 19, 2015 17:45
OFEV® (nintedanib*) approved in the EU for the treatment of IPF
Boehringer Ingelheim today announced that the European Commission (EC) has approved nintedanib* for the treatment of idiopathic pulmonary fibrosis (IPF), following an expedited review and positive CHM
January 19, 2015 11:00
Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis
Celgene International Sàrl (NASDAQ: CELG), a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission (EC) has granted marketing authorisation for OTEZLA® (apremila
January 16, 2015 13:10
Expression Analysis Announces 2014 Grant Winners
Expression Analysis (EA), a Quintiles company, today announced the winners of a grant program that provides scientists with leading-edge products and services to advance genomics research. In this six
January 15, 2015 23:30
Clinicians Worldwide Confirm Impact of UpToDate on Quality of Care in 2014
Wolters Kluwer Health (http://goo.gl/o2rWK), a leading global provider of information for healthcare professionals and students, announced today that clinicians worldwide accessed more than 314 millio
January 15, 2015 17:45
35 Partners from Industry and Academia to Join European Research Initiative for the Prevention of Alzheimer’s Dementia
The members of the EPAD initiative today announced the start of a novel collaboration between academic and private sectors to test innovative treatments for the prevention of Alzheimer’s dementia.
January 15, 2015 10:45
Boehringer Ingelheim and Vanderbilt University join forces to develop new Ras inhibitors for cancer treatment
Boehringer Ingelheim announced today that it has established a research alliance with Vanderbilt University and the cancer drug discovery laboratory of Professor Stephen W. Fesik, Ph.D., the Orrin H.
25 per page50 per page75 per page100 per page